These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 35875370)

  • 61. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
    Derosa S; Misztak P; Mingardi J; Mazzini G; Müller HK; Musazzi L
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jan; 128():110871. PubMed ID: 37793481
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ketamine for depression.
    Jelen LA; Stone JM
    Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Study protocol for SKIPMDD: subcutaneous ketamine infusion in palliative care patients with advanced life limiting illnesses for major depressive disorder (phase II pilot feasibility study).
    Lee W; Sheehan C; Chye R; Chang S; Loo C; Draper B; Agar M; Currow DC
    BMJ Open; 2021 Jun; 11(6):e052312. PubMed ID: 34183351
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Ketamine-Induced Glutamatergic Mechanisms of Sleep and Wakefulness: Insights for Developing Novel Treatments for Disturbed Sleep and Mood.
    Duncan WC; Ballard ED; Zarate CA
    Handb Exp Pharmacol; 2019; 253():337-358. PubMed ID: 28939975
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.
    Mathews DC; Henter ID; Zarate CA
    Drugs; 2012 Jul; 72(10):1313-33. PubMed ID: 22731961
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression.
    Drewniany E; Han J; Hancock C; Jones RL; Lim J; Nemat Gorgani N; Sperry JK; Yu HJ; Raffa RB
    J Clin Pharm Ther; 2015 Apr; 40(2):125-30. PubMed ID: 25545040
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine.
    Wohleb ES; Gerhard D; Thomas A; Duman RS
    Curr Neuropharmacol; 2017; 15(1):11-20. PubMed ID: 26955968
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Antidepressant-like effects of ketamine in a mouse model of serotonergic dysfunction.
    Wilson C; Li S; Hannan AJ; Renoir T
    Neuropharmacology; 2020 May; 168():107998. PubMed ID: 32061666
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fast-acting antidepressant activity of ketamine: highlights on brain serotonin, glutamate, and GABA neurotransmission in preclinical studies.
    Pham TH; Gardier AM
    Pharmacol Ther; 2019 Jul; 199():58-90. PubMed ID: 30851296
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ketamine for treatment-resistant depression: recent developments and clinical applications.
    Schwartz J; Murrough JW; Iosifescu DV
    Evid Based Ment Health; 2016 May; 19(2):35-8. PubMed ID: 27053196
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Targeting glutamate signalling in depression: progress and prospects.
    Murrough JW; Abdallah CG; Mathew SJ
    Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Breaking Sad: Unleashing the Breakthrough Potential of Ketamine's Rapid Antidepressant Effects.
    Feifel D
    Drug Dev Res; 2016 Dec; 77(8):489-494. PubMed ID: 27888525
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study.
    Carlson PJ; Diazgranados N; Nugent AC; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Manji HK; Zarate CA; Drevets WC
    Biol Psychiatry; 2013 Jun; 73(12):1213-21. PubMed ID: 23540908
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rapid treatments for depression: Endocannabinoid system as a therapeutic target.
    Sharafi A; Pakkhesal S; Fakhari A; Khajehnasiri N; Ahmadalipour A
    Neurosci Biobehav Rev; 2022 Jun; 137():104635. PubMed ID: 35351488
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The role of ketamine in treatment-resistant depression: a systematic review.
    Serafini G; Howland RH; Rovedi F; Girardi P; Amore M
    Curr Neuropharmacol; 2014 Sep; 12(5):444-61. PubMed ID: 25426012
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Keeping up with the clinical advances: depression.
    Ragguett RM; Tamura JK; McIntyre RS
    CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
    Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
    JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ketamine and the next generation of antidepressants with a rapid onset of action.
    Machado-Vieira R; Salvadore G; Diazgranados N; Zarate CA
    Pharmacol Ther; 2009 Aug; 123(2):143-50. PubMed ID: 19397926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.